Fresenius Medical Care offers $585m in notes

July 5, 2018 By Sarah Faulkner Leave a Comment

Fresenius Medical Care (NYSE:FMS; ETR:FRE) this week successfully placed notes with an aggregate principal amount of €500 million ($584.9 million).

The notes will mature in 7 years and have an annual coupon of 1.5%, the company noted. Fresenius reported that the issue price is 99.704% and the resulting yield amounts to 1.545%.

“The transaction was very well received by investors and substantially oversubscribed. The proceeds will be used for general corporate purposes, including the refinancing of upcoming maturities,” Fresenius said in a press release.

Last week, the medtech giant inked a $150 million strategic partnership with Humacyte, landing exclusive rights to commercialize Humacyte’s Humacyl bioengineered blood vessel technology.

Research Triangle Park, N.C.-based Humacyte is positioning its Humacyl human acellular vessel as a conduit for hemodialysis in patients with end-stage renal disease who cannot have fistula placement.

According to the terms of the deal, Fresenius Medical will be responsible for the marketing, sales and distribution of Humacyl following appropriate regulatory approval. Fresenius is also slated to make a $150 million equity investment to obtain a 19% fully diluted ownership stake in Humacyte, with the deal expected to close next month.

Inside Hologic's evolving definition of women's healthcare

Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

Medtech should think deeper about the problems its trying to solve
Medtech can improve by thinking more about the problems it is trying to solve and looking outside of normal avenues for inspiration. Jeff Karp, Brigham and Women’s Hospital, Harvard Medical School. For companies and academics aiming to innovate in the medical space, we often don’t spend enough time thinking about the problem we are trying… […]
5 tips for post-market medical device compliance
Post-market surveillance is an important process for medical device developers and an expectation of regulatory bodies that you follow through and have effective procedures. Jon Speer, Greenlight Guru In fact, post-market surveillance is a compliance issue that many companies get caught up with in audits or inspections. So how comfortable is your medtech company with the… […]
11 pediatric cardiovascular devices you need to know
A bandage-sized heart monitor, an extracorporeal blood pump that mimics the human heart, and a heart valve that can grow with a child were among the six winners of a contest yesterday in Philadelphia for innovative pediatric cardiovascular devices. The Pediatric Device Innovation Symposium organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at… […]
Meddux Development receives ISO 13485:2016 certification
Meddux Development announced that it has received ISO 13485:2016 certification for its quality management system. “The certification to ISO 13485:2016 allows Meddux to offer its customers a streamlined path from concept to first-in-human clinical trials, David Schechter, president of Meddux, said. “Meddux has developed a flexible and responsive QMS capable of handling the most critical… […]
6 questions to ask when designing polymer components for medical devices
Choosing the right polymer for the job can be a daunting task. Here are the right questions to ask before you begin the process. Karen Heroldt, PolyOne Distribution Choosing polymers is complicated in the high-stakes world of medical and healthcare devices. Materials can have varied tool design, molding and secondary processing requirements that can affect… […]
Medtech M&A remains hot: Here’s how
M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig. The number of medtech M&A deals soared by 50% in 2017 and… […]
Olympus touts line of needles for GI disease improvement
Olympus is touting its new EZ Shot 3 Plus 25 G needles that is designed to help improve the staging of GI disease. The 25 G needle is an addition to the EZ Shot 3 Plus 19 G and 22 G needles that Olympus already markets. Olympus’s new EZ Shot 3 Plus 25 G needles… […]
Mindray North America picks Eastman medical polymers for patient monitors
Mindray is using Eastman’s medical polymers in its present generation of patient monitors in order to improve chemical resistance to cleaning/disinfection agents and increase device longevity, the companies recently announced. Thanks to the Eastman polymers, Mindray’s Passport series of bedside monitors, T1 monitor/module and Accutorr series of spot check monitors are now fully compatible with more than… […]
Cincinnati Children’s researchers report progress growing a human esophagus in a lab
It’s possible to use pluripotent stem cells to grow human esophageal organoids — another step toward the goal of someday bioengineering the entire esophagus and human gastrointestinal system in a lab, according to researchers at Cincinnati Children’s Center for Stem Cell and Organoid Medicine (CuSTOM). The Cincinnati Children’s researchers describe the advance as a first. Pluripotent stem… […]
How strong patent portfolios attract strategic investments and deals
Amassing strong patent portfolios helps medical device companies attract interest from strategic investors and potential acquirers. David J. Dykeman, Greenberg Traurig and Patrick West, Mirus Capital Advisors The medical device industry has demonstrated strong and sustainable growth in recent years. Given the aging population, increasing incidence of chronic and lifestyle diseases, emergence of artificial intelligence (AI)… […]
NucleusHealth wins investment from large Ohio health system
Cloud-based medical image exchange company NucleusHealth has landed an undisclosed “strategic investment” from Mercy Health, an Ohio–based health care system that is now a minority investor in the San Diego, Calif.-based company. NucleusHealth will use the money to help deliver Nucleus.io, the first cloud-based Picture Archiving Communications System (PACS) platform designed to use the security, scalability and… […]